Bayer PLC & others –v- NHS Darlington CCG & others

19th to 22nd November 2019

This case concerns the legality of the Respondents’ policy headed `Treatment for Age-Related Macular Degeneration.’ The policy states that a drug, Avastin, will be offered to certain patients with an Age-Related Macular Degeneration disease (`Wet AMD’) as the preferred treatment option. The claimants contend that this is unlawful.

Click here for lower court Judgment:

https://www.bailii.org/ew/cases/EWHC/Admin/2018/2465.html

View hearing:

Day 1

Part 1

Part 2

Day 2

Part 1

Part 2

Day 3

Part 1

Part 2

Day 4

Part 1

Part 2